NEW YORK (GenomeWeb) – Med Fusion, a clinical laboratory and clinical trials service organization, has selected N-of-One to interpret the results of Med Fusion's new HemeSeq tests.
Med Fusion's HemeSeq profiles help physicians diagnose and predict disease progression as well as identify relevant clinical trial and treatment options for patients living with hematologic diseases. HemeSeq profiles can be ordered as standalone tests by treating physicians or as part of Med Fusion's Comprehensive Heme (HEMC) testing service which includes information from flow cytometry, morphology, chromosomal analysis, FISH, and molecular testing. The lab is currently developing new tests for myelodysplastic syndromes among other conditions that will be available later this year.
Under the terms of its agreement, N-of-One will interpret data from existing HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and myeloproliferative neoplasms. Partnering with N-of-One will help Med Fusion "address our growing volume of molecular diagnostic tests for patients living with hematologic neoplasms," Med Fusion CEO Jon Hart said in a statement.
"Our vision is to provide responsible precision medicine solutions that enable best-in-class patient care," he said. "We selected N-of-One because we believe the quality of their work will help support this vision by providing the very best diagnostic, clinical trial, and treatment options to our oncologist clients."
Financial and other terms of the agreement were not disclosed.
Last week, N-of-One said that it had signed an agreement to provide analysis support for Inivata's Invision liquid biopsy product line.